TrialMedicine2019

A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) versus Viread for the treatment of chronic hepatitis B: First-stage results at week 48.

Rong-Yue Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.